Literature DB >> 26996941

Molecular Mechanism of Pin1-Tau Recognition and Catalysis.

Timo Eichner1, Steffen Kutter1, Wladimir Labeikovsky1, Vanessa Buosi1, Dorothee Kern2.   

Abstract

Human peptidyl-prolyl isomerase (PPIase) Pin1 plays key roles in developmental processes, cell proliferation, and neuronal function. Extensive phosphorylation of the microtubule binding protein tau has been implicated in neurodegeneration and Alzheimer's disease. For the past 15years, these two players have been the focus of an enormous research effort to unravel the biological relevance of their interplay in health and disease, resulting in a series of proposed molecular mechanism of how Pin1 catalysis of tau results in biological phenotypes. Our results presented here refute these mechanisms of Pin1 action. Using NMR, isothermal calorimetry (ITC), and small angle x-ray scattering (SAXS), we dissect binding and catalysis on multiple phosphorylated tau with particular emphasis toward the Alzheimer's associated AT180 tau epitope containing phosphorylated THR231 and SER235. We find that phosphorylated (p-) SER235-PRO, but not pTHR231-PRO, is exclusively catalyzed by full-length Pin1 and isolated PPIase domain. Importantly, site-specific measurements of Pin1-catalysis of CDK2/CycA-phosphorylated full-length tau reveal a number of sites that are catalyzed simultaneously with different efficiencies. Furthermore, we show that the turnover efficiency at pSER235 by Pin1 is independent of both the WW domain and phosphorylation on THR231. Our mechanistic results on site-specific binding and catalysis together with the lack of an increase of dephosphorylation rates by PP2A counter a series of previously published models for the role of Pin1 catalysis of tau in Alzheimer's disease. Together, our data reemphasize the complicated scenario between binding and catalysis of multiple phosphorylated tau by Pin1 and the need for directly linking biological phenotypes and residue-specific turnover in Pin1 substrates.
Copyright © 2016. Published by Elsevier Ltd.

Entities:  

Keywords:  binding kinetics; molecular mechanism; peptidyl-prolyl cis/trans isomerization; phosphorylation; protein dynamics

Mesh:

Substances:

Year:  2016        PMID: 26996941     DOI: 10.1016/j.jmb.2016.03.009

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  8 in total

1.  Molecular Mechanism of the Pin1-Histone H1 Interaction.

Authors:  Dinusha Jinasena; Robert Simmons; Hawa Gyamfi; Nicholas C Fitzkee
Journal:  Biochemistry       Date:  2018-12-18       Impact factor: 3.162

Review 2.  Peptidyl-Proline Isomerases (PPIases): Targets for Natural Products and Natural Product-Inspired Compounds.

Authors:  Bryan M Dunyak; Jason E Gestwicki
Journal:  J Med Chem       Date:  2016-07-25       Impact factor: 7.446

3.  Neighboring phosphoSer-Pro motifs in the undefined domain of IRAK1 impart bivalent advantage for Pin1 binding.

Authors:  Monique J Rogals; Alexander I Greenwood; Jeahoo Kwon; Kun Ping Lu; Linda K Nicholson
Journal:  FEBS J       Date:  2016-11-20       Impact factor: 5.542

4.  A Phosphoramidate Strategy Enables Membrane Permeability of a Non-nucleotide Inhibitor of the Prolyl Isomerase Pin1.

Authors:  Daniel M C Schwarz; Sarah K Williams; Maxwell Dillenburg; Carston R Wagner; Jason E Gestwicki
Journal:  ACS Med Chem Lett       Date:  2020-08-10       Impact factor: 4.345

Review 5.  The role of prostate tumor overexpressed 1 in cancer progression.

Authors:  Verónica Cánovas; Matilde Lleonart; Juan Morote; Rosanna Paciucci
Journal:  Oncotarget       Date:  2017-02-14

Review 6.  Pin1 Modulation in Physiological Status and Neurodegeneration. Any Contribution to the Pathogenesis of Type 3 Diabetes?

Authors:  Marzia Bianchi; Melania Manco
Journal:  Int J Mol Sci       Date:  2018-08-08       Impact factor: 5.923

7.  Structure analysis suggests Ess1 isomerizes the carboxy-terminal domain of RNA polymerase II via a bivalent anchoring mechanism.

Authors:  Kevin E W Namitz; Tongyin Zheng; Ashley J Canning; Nilda L Alicea-Velazquez; Carlos A Castañeda; Michael S Cosgrove; Steven D Hanes
Journal:  Commun Biol       Date:  2021-03-25

Review 8.  When Good Kinases Go Rogue: GSK3, p38 MAPK and CDKs as Therapeutic Targets for Alzheimer's and Huntington's Disease.

Authors:  Santosh R D'Mello
Journal:  Int J Mol Sci       Date:  2021-05-31       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.